Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.
An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.
Gilead Sciences reports fourth-quarter and 2014 earnings on Tuesday after the market close.
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.